{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the 95% confidence interval was not calculable/available (not estimable \\[NE\\]) because an insufficient number of participants reached the event at the final time point for assessment (3 of 7 responders had an event).","groupId":"OG000","lowerLimit":"57","upperLimit":"NA","value":"219"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Duration of response (DOR) was calculated separately for subjects with clinical benefit response or overall response. DOR is defined as the time from first evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 of a 28 day cycle","id":"OG000","title":"Carfilzomib (A0) for (ORR)"}],"paramType":"MEDIAN","populationDescription":"Subjects with overall response within the response-evaluable population were included in the analysis of DOR. See analysis population description of response-evaluable population above.","reportingStatus":"POSTED","timeFrame":"Response assessments same as described in primary outcome measure","title":"Duration of Response (A0 Only)","type":"SECONDARY","unitOfMeasure":"days"}